Xcovery is presenting a mini-oral presentation entitled:


Response to Ensartinib in TKI naïve ALK+ NSCLC patients

Heather A. Wakelee, Rachel E. Sanborn, Jorge Nieva,  Saiama Naheed Waqar, Christina E. Brzezniak, Jessica Bauman, Joel W. Neal,  Gary Dukart,  Fenlai Tan, Kimberly Harrow, Chris Liang, Leora Horn

Ensartinib has shown clinical activity in patients harboring an ALK alteration including EML4-ALK fusion or point mutation such as T1151M, G1269A, L1196M, G1202R and V1149M. Xcovery is presenting preliminary results from the ongoing eXalt2 phase 2 study. Overall response rates in the ALK TKI naïve sub-population are 92{78c6e071319c08d812d0e84a9525ce4b74a9cc2d8ca16eea73b7762889119219} in NGS confirmed ALK+ subjects.

Durable responses and clinically meaningful intracranial responses were observed. Ensartinib is generally well tolerated with the most common AE, rash, being easily treated. Responses are also seen in patients treated with at least one 2nd generation ALK TKI and in patients with prior crizotinib. The eXalt3, a phase III trial, is ongoing, comparing ensartinib to crizotinib in TKI naïve ALK-positive NSCLC patients.